• Vaccine Name: VSV-based vaccine expressing MBGV GP
• Target Pathogen: Marburg Virus
• Target Disease: Hemorrhagic fever
• Vaccine Ontology ID: VO_0004136
• Type: Recombinant vector vaccine
• Antigen: Marburg virus (MBGV) glycoprotein (GP) was used. A recombinant vesicular stomatitis virus (VSV) was used as a vector. The vaccine utilizes the VSVΔG/MARVGP-Musoke strain (Daddario-DiCaprio et al., 2006).
• GP from Musoke Marburgvirus gene engineering:
  • Type: Recombinant protein preparation
  • Description: The ORF for the glycoproteins were generated by PCR and cloned into GP-lacking VSV vectors (Daddario-DiCaprio et al., 2006).
  • Detailed Gene Information: Click Here.
• Preparation: The ORF for the glycoproteins for the MARV-Musoke and the ZEBOV were generated by PCR and cloned into GP-lacking VSV vectors. Infectious clones for the VSV Indiana serotype were used (Daddario-DiCaprio et al., 2006).
  
• Virulence: All animals developed high anti-MARV IgG antibody levels by the challenge time, while low levels of anti-MARV neutralizing antibodies were observed for a large percentage of animals vaccinated with VSVΔG/MARVGP-Musoke at the challenge day. Protection of the host subjects injected with the VSVΔG/MARVGP-Musoke vaccine appears to be associated with humoral response, as opposed to cellular immune response (Daddario-DiCaprio et al., 2006).
  

Monkey Response

• Host Strain: cynomolgus macaques
• Vaccination Protocol: Nine adult macaques were used. Seven were injected intramuscularly with the VSVΔG/MARVGP-Musoke vaccine, and two recieved VSVΔG/ZEBOVGP as experimental controls (Daddario-DiCaprio et al., 2006).
• Persistence: Not noted.
• Immune Response: With the use of purified virus particles for an antigen source, immunoglobulin G (IgG) antibodies against MARV were detected through an enzyme-linked immunosorbent assay (ELISA). A transient and low-level recombinant VSV viremia was detected through virus isolation on the third day after vaccination in plasma from four of the VSVΔG/MARVGP-Musoke vaccinated animals. Both the MARV-Angola-challenged control animal and the MARV-Ravn-challenged control animal developed high titers in the blood, detected by plaque assay (Daddario-DiCaprio et al., 2006).
  
• Side Effects: After either vaccination with VSVΔG/MARVGP-Musoke or after the MARV challenge, none of the animals showed any evidence of clinical illness (Daddario-DiCaprio et al., 2006).
• Challenge Protocol: All animals were challenged with either MARV-Angola, MARV-Musoke, or MARV-Ravn 28 days after immunization (Daddario-DiCaprio et al., 2006).
• Efficacy: VSVΔG/MARVGP-Musoke vector does protect nonhuman primates against a lethal challenge with both Ravn and Angola strains of MBGV. This approach seems almost as successful as the use of VEEV MARV GP and/or VEEV MARV NP, which protected NHP against a lethal homologous challenge, but did not protect against a lethal heterologous Ravn challenge (Daddario-DiCaprio et al., 2006).